State Street SPDR S&P Biotech ETF
XBI
627 hedge funds and large institutions have $9.7B invested in State Street SPDR S&P Biotech ETF in 2025 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 160 increasing their positions, 279 reducing their positions, and 105 closing their positions.
33.37% more ownership
Funds ownership: 139.93% → 173.3% (+33%)
28% more capital inflows, than outflows
Capital inflows: $1.39B | Capital outflows: $1.09B
0% more funds holding in top 10
Funds holding in top 10: 15 → 15 (0)
9% less funds holding
Funds holding: 687 → 627 (-60)
34% less call options, than puts
Call options by funds: $1.48B | Put options by funds: $2.24B
43% less repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 279
56% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$399M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$291M |
| 3 |
Citigroup
New York
|
+$182M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$59.4M |
| 5 |
Jefferies Financial Group
New York
|
+$50.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$246M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$199M |
| 3 |
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$48.7M |
| 4 |
Squarepoint
New York
|
-$38.6M |
| 5 |
J. Safra Asset Management
New York
|
-$25.2M |
XBI Hedge Fund Activity: Q2 2025 in Review
627 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2025, worth a combined $9.7B — up 5.8% from $9.2B a quarter earlier.
Sellers outnumbered buyers: 105 funds closed out of XBI and 46 opened new positions — a net loss of 59 holders — while 279 trimmed existing stakes and 160 added.
The largest buyer was Goldman Sachs, adding an estimated $399M. The largest seller was UBS Group, cutting an estimated $246M.
- 627 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2025, down from 687 in Q1 2025.
- Funds reported $9.7B of State Street SPDR S&P Biotech ETF stock for Q2 2025, up 5.8% quarter-over-quarter.
- 46 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2025 and 105 closed out, a net change of -59 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2025 was Goldman Sachs, an estimated $399M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2025 was UBS Group, an estimated $246M sold.
Based on aggregated 13F filings for Q2 2025.